Neuroprotective strategies in Alzheimer's disease.
In addition to strategies designed to decrease amyloid beta (A beta) levels, it is likely that successful Alzheimer's disease (AD) therapeutic regimens will require the concomitant application of neuroprotective agents. Elucidation of pathophysiological processes occurring in AD and identification of the molecular targets mediating these processes point to potential high-yield neuroprotective strategies. Candidate neuroprotective agents include those that interact specifically with neuronal targets to inhibit deleterious intraneuronal mechanisms triggered by A beta and other toxic stimuli. Strategies include creating small molecules that block A beta interactions with cell surface and intracellular targets, down-regulate stress kinase signaling cascades, block activation of caspases and expression of pro-apoptotic proteins, and inhibit enzymes mediating excessive tau protein phosphorylation. Additional potential neuroprotective compounds include those that counteract loss of cholinergic function, promote the trophic state and plasticity of neurons, inhibit accumulation of reactive oxygen species, and block excitotoxicity. Certain categories of compounds, such as neurotrophins or neurotrophin small molecule mimetics, have the potential to alter neuronal signaling patterns such that several of these target actions might be achieved by a single agent.
Longo
Frank M
FM
Department of Neurology, University of North Carolina, Chapel Hill, North Carolina 27599, USA. longof@glial.med.unc.edu
Massa
Stephen M
SM
D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D015398:Signal Transduction / Q000502:physiology*
D018696:Neuroprotective Agents
Neurobiol Dis. 1999 Oct;6(5):440-9
10527810
Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):31-49
12769633
J Biol Chem. 1993 Nov 5;268(31):22959-62
8226807
Adv Drug Deliv Rev. 2002 Dec 7;54(12):1603-13
12453677
Prog Neurobiol. 1999 Feb;57(4):451-84
10080385
Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):246-57
9701676
J Neurosci. 2003 Jul 2;23(13):5531-5
12843253
Biochem J. 2003 May 1;371(Pt 3):789-98
12534344
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):569-73
1309947
Ann N Y Acad Sci. 1998 Jun 19;845:32-45
9668341
J Neurochem. 1999 Mar;72(3):1327-30
10037507
Eur Neurol. 2000;44(3):172-80
11053967
Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):705-12
12188103
Eur J Pharmacol. 2000 Mar 30;393(1-3):255-63
10771022
Curr Opin Neurobiol. 2002 Jun;12(3):260-7
12049931
Neuron. 2003 Mar 27;37(6):889-90
12670416
Trends Neurosci. 2003 Feb;26(2):73-80
12536130
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10075-8
1359534
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12108-13
10518584
Amyloid. 2003 Mar;10(1):1-6
12762134
Cell Mol Neurobiol. 2001 Jun;21(3):173-213
11569534
Neurobiol Aging. 2002 Sep-Oct;23(5):795-807
12392783
Mol Cell Neurosci. 2002 Sep;21(1):15-28
12359148
J Neuropathol Exp Neurol. 2001 Sep;60(9):829-38
11556539
Science. 2002 Jul 19;297(5580):353-6
12130773
Eur J Pharmacol. 1991 Jun 6;198(2-3):215-7
1864308
Nat Rev Neurosci. 2002 Dec;3(12):965-74
12461553
J Mol Neurosci. 2002 Aug-Oct;19(1-2):107-11
12212765
Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3
2174172
J Neurochem. 2001 May;77(3):849-63
11331414
Nat Med. 2002 Sep;8(9):936-8
12205453
JAMA. 2002 Jun 26;287(24):3223-9
12076218
J Biol Chem. 2000 Sep 22;275(38):29868-74
10896671
J Neurochem. 2002 Aug;82(3):674-82
12153491
N Engl J Med. 1997 Apr 24;336(17):1216-22
9110909
Bipolar Disord. 2002 Jun;4(3):153-65
12180271
Peptides. 2002 Jul;23(7):1271-83
12128084
JAMA. 2002 Jun 26;287(24):3230-7
12076219
J Neurosci. 2002 Jan 1;22(1):103-13
11756493
Lancet Neurol. 2002 May;1(1):51-7
12849545
Ann Neurol. 2000 Dec;48(6):913-8
11117548
Ann N Y Acad Sci. 2000;924:26-8
11193797
Mol Cell Neurosci. 2001 Aug;18(2):210-20
11520181
Free Radic Res. 2002 Dec;36(12):1307-13
12607822
Trends Pharmacol Sci. 2000 Mar;21(3):93-8
10689362
Prog Neurobiol. 1998 Dec;56(5):541-69
9775403
J Neurosci Res. 2001 Jul 1;65(1):45-53
11433428
Am J Pathol. 2002 Nov;161(5):1869-79
12414533
J Cell Biol. 1996 Dec;135(5):1341-54
8947555
Exp Neurol. 2002 Nov;178(1):104-11
12460612
J Biol Chem. 2001 Apr 27;276(17):13541-6
11278378
Trends Neurosci. 2002 Feb;25(2):79-84
11814559
Trends Neurosci. 2003 Apr;26(4):207-14
12689772
Drug News Perspect. 2002 Nov;15(9):549-557
12677194
Science. 1992 Oct 9;258(5080):304-7
1411529
J Biol Chem. 2002 May 17;277(20):17649-56
11882652
J Comp Neurol. 2000 Mar 13;418(3):241-54
10701824
Science. 2002 Oct 25;298(5594):789-91
12399581
Neurosignals. 2002 Sep-Oct;11(5):236-50
12566925
JAMA. 2002 Jun 26;287(24):3261-3
12076225
Neuroreport. 1995 Oct 2;6(14):1875-9
8547588
J Clin Invest. 2003 Jan;111(1):11-8
12511580
J Alzheimers Dis. 2001 Feb;3(1):41-48
12214071
J Neurosci. 2001 Oct 1;21(19):7551-60
11567045
Am J Public Health. 1998 Sep;88(9):1337-42
9736873
Arch Neurol. 2003 Feb;60(2):203-8
12580704
J Biol Chem. 2002 Jan 25;277(4):2573-8
11707464
Neuron. 2001 Jun;30(3):665-76
11430801
Prog Neurobiol. 2002 Jun;67(3):203-33
12169297
J Mol Neurosci. 2002 Dec;19(3):337-8
12540061
Neuropharmacology. 1993 Dec;32(12):1337-50
8152525
Prog Brain Res. 2000;128:333-47
11105692
Proc Nutr Soc. 2002 May;61(2):191-202
12133201
J Neurovirol. 2002 Dec;8(6):529-38
12476347
Curr Opin Neurobiol. 1996 Oct;6(5):661-6
8937831
Exp Neurol. 2003 Apr;180(2):144-55
12684028
Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):221-33
11146125
J Neurosci. 2002 May 1;22(9):3376-85
11978814
Arch Neurol. 2002 Jun;59(6):972-6
12056933
J Biol Chem. 2002 Nov 1;277(44):42060-5
12191990
J Mol Neurosci. 2002 Aug-Oct;19(1-2):101-5
12212764
Biochem Pharmacol. 2002 Feb 15;63(4):563-7
11992623
J Mol Neurosci. 2002 Dec;19(3):303-7
12540056
J Mol Neurosci. 2000 Feb-Apr;14(1-2):61-8
10854037
Annu Rev Pharmacol Toxicol. 2003;43:545-84
12415125
Restor Neurol Neurosci. 1998;13(1-2):75-83
12671289
J Biol Chem. 2003 Jul 25;278(30):28294-302
12730216
Annu Rev Neurosci. 2001;24:1217-81
11520933
Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):225-39
12787561
Brain Res. 2002 Dec 20;958(1):210-21
12468047
Eur Neurol. 2000;44(4):236-41
11096224
Prog Neurobiol. 2002 Oct;68(3):209-45
12450488
Med Clin North Am. 2002 May;86(3):615-27
12168561
Arch Neurol. 2003 Jun;60(6):843-8
12810489
N Engl J Med. 2003 Apr 3;348(14):1333-41
12672860
Brain Res. 1993 Sep 3;621(1):35-49
8221072
J Neurosci. 1999 Sep 15;19(18):8009-26
10479701
Ann N Y Acad Sci. 1994 Dec 15;747:162-71
7847669
Nat Rev Neurosci. 2003 Apr;4(4):299-309
12671646
Free Radic Biol Med. 2002 Nov 1;33(9):1194-9
12398927
J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53
12212772
J Neurosci. 2001 Nov 1;21(21):8370-7
11606625
CNS Drugs. 2003;17(9):641-52
12828500
Nature. 2000 Oct 12;407(6805):802-9
11048732
J Cell Biol. 2002 Feb 4;156(3):519-29
11815632
J Neurosci Res. 2002 Nov 1;70(3):380-91
12391601
Eur J Neurosci. 1994 Apr 1;6(4):668-71
8025717
Biol Psychiatry. 2001 Feb 1;49(3):289-99
11230880
J Neurochem. 2001 Apr;77(1):157-64
11279271
J Neurochem. 2001 Jan;76(2):435-41
11208906
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10439-44
11504920
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4772-7
9114067
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4086-91
9108109
J Neurosci Res. 1997 Apr 1;48(1):1-17
9086177
Exp Neurol. 2002 Nov;178(1):91-103
12460611